Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540904 | 0.98 | GPR3 (0.35) | GPR3POLBKMT2AACHEBCHE | |
| Hydrochloric Acid SCHEMBL995806 | 0.96 | GPR3 (0.34) | GPR3POLBKMT2AACHEBCHE | |
| Hydrochloric Acid SCHEMBL6858048 | 0.96 | GPR3 (0.34) | GPR3POLBKMT2AACHEBCHE | |
| Hydrochloric Acid SCHEMBL6862745 | 0.96 | GPR3 (0.34) | GPR3POLBKMT2AACHEBCHE | |
| SCHEMBL28790426 | 0.95 | GPR3 (0.33) | GPR3POLBKMT2AACHEBCHE | |
| SCHEMBL29171300 | 0.93 | GPR3 (0.32) | GPR3POLBKMT2AACHEBCHE | |
| SCHEMBL7630038 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL8022568 | 0.82 | GAA (0.30) | — | |
| SCHEMBL4480345 | 0.81 | — | — | |
| SCHEMBL6908346 | 0.80 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179914-A1 | METHOD FOR PRODUCING CATALYST | POLYPLASTICS CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| EP-1070072-A4 | SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS | BOULDER SCIENT CO (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1150986-A4 | SILYL AMINES | BOULDER SCIENT CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6410767-B2 | USING N-SILYLATED MONO(CYCLOPENTADIENYL) LIGAND | BOULDER SCIENTIFIC CO. | 2002-06-25 | — | — | US | disclosed |
| US-20010056199-A1 | Silylated and N-silylated compound synthesis | BOULDER SCIENTIFIC COMPANY | 2001-12-27 | — | — | US | disclosed |
| EP-1150986-A1 | SILYL AMINES | BOULDER SCIENTIFIC COMPANY (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001038334-A1 | SILYL AMINES | BOULDER SCIENTIFIC COMPANY (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6180810-B1 | SILYL AMINES WHICH BOND COVALENTLY TO METAL CENTER OF COMPLEX TO PROVIDE OLEFIN POLYMERIZATION CATALYST COMPONENT | BOULDER SCIENTIFIC COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-1070072-A1 | SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS | BOULDER SCIENTIFIC COMPANY (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000047587-A1 | SILYLATED AND N-SILYLATED COMPOUND SYNTHESIS | BOULDER SCIENTIFIC COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
| US-6087518-A | Silylated and N-silylated compound synthesis | BOULDER SCIENTIFIC COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056199-A1 | Silylated and N-silylated compound synthesis | LSS, NCL, FNTA | GPR3 2349/4885POLB 3911/4885KMT2A 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.